Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 16/20 | 0.64 |
| ▸ | TCF7L2 | Q9NQB0 | 16/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13797216 | 0.86 | CTNNB1 (0.64) | CTNNB1TCF7L2 | |
| SCHEMBL13797218 | 0.86 | CTNNB1 (0.53) | CTNNB1TCF7L2MAPTXDH | |
| SCHEMBL13797204 | 0.80 | CTNNB1 (0.86) | CTNNB1TCF7L2 | |
| SCHEMBL13797649 | 0.78 | MAPT (0.56) | CTNNB1TCF7L2MAPTXDHMEN1 | |
| SCHEMBL4181522 | 0.78 | CTNNB1 (1.00) | CTNNB1TCF7L2 | |
| SCHEMBL13797207 | 0.77 | CTNNB1 (0.82) | CTNNB1TCF7L2 | |
| SCHEMBL13797222 | 0.76 | CTNNB1 (0.67) | CTNNB1TCF7L2MEN1KMT2A | |
| SCHEMBL13797215 | 0.76 | CTNNB1 (0.72) | CTNNB1TCF7L2 | |
| SCHEMBL13797212 | 0.75 | CTNNB1 (0.75) | CTNNB1TCF7L2 | |
| SCHEMBL4175284 | 0.73 | CTNNB1 (1.00) | CTNNB1TCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | CTNNB1 1772/4885TCF7L2 1324/4885MAPT 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.